Resistance on the Latest Oral and Intravenous P2Y12 ADP Receptor Blockers in Patients with Acute Coronary Syndromes: Fact or Myth?

Novel P2Y12 ADP receptor blockers (ADPRB) should be preferred in dual-antiplatelet therapy in patients with acute coronary syndrome. Nevertheless, there are still patients who do not respond optimally to novel ADP receptor blocker therapy, and this nonoptimal response (so-called “high on-treatment p...

Descripción completa

Detalles Bibliográficos
Autores principales: Blaško, Peter, Samoš, Matej, Bolek, Tomáš, Stančiaková, Lucia, Škorňová, Ingrid, Péč, Martin Jozef, Jurica, Jakub, Staško, Ján, Mokáň, Marián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737839/
https://www.ncbi.nlm.nih.gov/pubmed/36498785
http://dx.doi.org/10.3390/jcm11237211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737839/
https://www.ncbi.nlm.nih.gov/pubmed/36498785
http://dx.doi.org/10.3390/jcm11237211

Ejemplares similares